Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.47
-0.0100-0.40%
Post-market: 2.45-0.0200-0.81%19:58 EDT
Volume:4.71M
Turnover:11.52M
Market Cap:2.11B
PE:-3.99
High:2.50
Open:2.47
Low:2.39
Close:2.48
Loading ...

BRIEF-Immunitybio Receives FDA Rmat Designation For Anktiva® And Car-Nk

Reuters
·
28 Feb

Immunitybio Receives FDA Rmat Designation for Anktiva® and Car-Nk for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

THOMSON REUTERS
·
28 Feb

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Business Wire
·
28 Feb

BUZZ-ImmunityBio rises as FDA approves alternative to Merck's scarce bladder cancer vaccine

Reuters
·
20 Feb

BRIEF-FDA Authorizes Immunitybio To Provide Rbcg To Urologists

Reuters
·
19 Feb

ImmunityBio Gets FDA Authorization for Expanded Access to Recombinant BCG for Bladder Cancer Treatment

MT Newswires Live
·
19 Feb

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
19 Feb

Immunitybio Inc - Thousands of Vials of Rbcg Available to End Tice Bcg Shortage

THOMSON REUTERS
·
19 Feb

Immunitybio Inc: Supplies of Rbcg Are NOW Available, With Shipments Set to Begin Immediately via an FDA Expanded Access Program

THOMSON REUTERS
·
19 Feb

ImmunityBio's Application for Anktiva Approved for Review in UK

MT Newswires Live
·
14 Feb

ImmunityBio announces UK acceptance of Anktiva marketing application

TIPRANKS
·
14 Feb

Immunitybio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for Anktiva® for the Treatment of Patients With Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

THOMSON REUTERS
·
14 Feb

Why Immunitybio Inc. (IBRX) Soared on Thursday

Insider Monkey
·
31 Jan

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

Dow Jones
·
29 Jan

ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy

MT Newswires Live
·
29 Jan

ImmunityBio enters collaboration with BeiGene on Anktiva trial

TIPRANKS
·
29 Jan

BRIEF-Immunitybio To Submit BLA In 2025 Based On Quilt 3.055 Data

Reuters
·
29 Jan

Immunitybio Announces Collaboration With Beigene on Confirmatory Phase 3 Trial of Anktiva® and Pd-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

THOMSON REUTERS
·
29 Jan

Immunitybio Inc - to Submit Bla in 2025 Based on Quilt 3.055 Data

THOMSON REUTERS
·
29 Jan

Immunitybio Inc - Patent for Anktiva and CPI Combinations Extends to 2035

THOMSON REUTERS
·
29 Jan